Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Total Non-Current Liabilities (2018 - 2021)

Cue Biopharma's Total Non-Current Liabilities history spans 4 years, with the latest figure at $17.9 million for Q4 2021.

  • For Q4 2021, Total Non-Current Liabilities fell 4.15% year-over-year to $17.9 million; the TTM value through Dec 2021 reached $17.9 million, down 4.15%, while the annual FY2021 figure was $17.9 million, 4.15% down from the prior year.
  • Total Non-Current Liabilities for Q4 2021 was $17.9 million at Cue Biopharma, up from $16.7 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $18.7 million in Q4 2020 and bottomed at $3.0 million in Q2 2018.
  • The 4-year median for Total Non-Current Liabilities is $15.1 million (2019), against an average of $13.2 million.
  • The largest annual shift saw Total Non-Current Liabilities surged 408.1% in 2019 before it dropped 20.85% in 2020.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $6.2 million in 2018, then soared by 109.16% to $13.0 million in 2019, then soared by 43.69% to $18.7 million in 2020, then fell by 4.15% to $17.9 million in 2021.
  • Per Business Quant, the three most recent readings for CUE's Total Non-Current Liabilities are $17.9 million (Q4 2021), $16.7 million (Q2 2021), and $17.7 million (Q1 2021).